McKesson (MCK) Q4 2026 Earnings Transcript

McKesson reported fiscal 2026 adjusted EPS of $39.11, up 18%, on 12% revenue growth to $403 billion and 15% higher adjusted operating profit of $6.5 billion, while fourth-quarter EPS rose 16% to $11.69. Management guided fiscal 2027 adjusted EPS to $43.80-$44.60, implying 12%-14% growth, and reaffirmed long-term targets while highlighting $5.1 billion returned to shareholders, a new $5 billion buyback authorization, and continued progress on the Medical-Surgical Solutions separation. Segment performance remained strong across North American Pharma, oncology/multispecialty, and technology solutions, supported by automation and AI-driven efficiency gains.

Analysis

The key signal is not just another clean quarter; it is that the business is compounding while simultaneously simplifying the equity story. The market should care more about the separation mechanics than the headline growth rate: moving the medical-surgical asset toward an independent capital structure plus minority monetization creates a visible pool of capital that is likely to be recycled into buybacks, which mechanically supports near-term EPS even if organic growth moderates. That makes the stock behave less like a pure distributor and more like a self-funding capital-return compounder with an embedded sum-of-the-parts catalyst.

The second-order read-through is that the highest-quality growth is now concentrated in specialty/community oncology and access-tech, where network density and workflow integration are becoming harder to replicate. That should pressure smaller specialty distributors and point solutions that compete on a narrower feature set, because McKesson is bundling distribution, access, data, and physician productivity into one relationship. AI is not the headline here, but it is already showing up in working capital, staffing efficiency, and provider stickiness; that combination can sustain margin expansion even if pricing in commodity distribution remains under pressure.

The main risk is that consensus may be extrapolating too cleanly from a year of strong execution into a more lumpy next year. Prescription-tech revenue is inherently volatile, and the GLP-1 mix appears to be normalizing sequentially; if launch cadence or payer behavior softens, the market could start to question whether operating profit can outgrow revenue at the current pace. A second risk is transaction execution: any delay in the medical-surgical separation, or a higher-than-expected tax/interest drag from financing, would postpone the buyback-driven EPS uplift and compress the near-term rerating case.

Key Decisions for Investors

• Long MCK outright over 3-6 months: the setup is still favorable because capital returns plus separation optionality should support the multiple; risk/reward is attractive as long as the transaction remains on track.
• Pair trade: long MCK / short a basket of lower-quality healthcare distributors or services names with less scale and weaker capital return; thesis is that McKesson’s network density and buyback capacity will compound share in a slower macro backdrop.
• Buy MCK call spreads for the next 2-3 quarters if you expect the market to rerate the stock on separation milestones; the best catalyst window is around regulatory approval and any incremental buyback announcement.
• Hedge with a tactical short or put spread in the event of separation delay headlines; if the transaction slips, the market will likely de-rate the stock on lower near-term capital deployment visibility.
• Avoid chasing the move in pure momentum terms; add on any post-earnings digestion because the more durable upside is tied to execution over the next 6-12 months, not to a single quarter print.